Stoke Therapeutics reports 55% reduction in convulsive seizures in Phase 1/2a study of STK-001 in Dravet syndrome

Stoke Therapeutics, Inc.

55% median reduction in convulsive seizure frequency from baseline in 6 patients treated with three doses of 45mg STK-001.
5/6 (83%) patients showed reductions; 4/6 (67%) had >50% reduction from baseline.
STK-001 up to 45mg well-tolerated; 27% (15/55) of patients had treatment-related AEs, all mild/moderate, no withdrawals.
Reductions in seizure frequency maintained in SWALLOWTAIL open-label extension; trend toward improvement in executive function (BRIEF-P).
One-year BUTTERFLY observational data showed little change in cognition without STK-001 treatment, highlighting disease progression.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.